



**HAL**  
open science

## **Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA-FLUO Trial**

Olivier J. Rascol, Valérie Cochen de Cock, Anne Pavy-Le Traon, Alexandra Foubert-Samier, Claire Thalamas, Agnes Sommet, Vanessa Rousseau, Santiago Perez-Lloret, Margherita Fabbri, Jean Philippe Azulay, et al.

► **To cite this version:**

Olivier J. Rascol, Valérie Cochen de Cock, Anne Pavy-Le Traon, Alexandra Foubert-Samier, Claire Thalamas, et al.. Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA-FLUO Trial. *Movement Disorders*, 2021, 36 (7), pp.1704-1711. 10.1002/mds.28569 . hal-03190779

**HAL Id: hal-03190779**

**<https://hal.science/hal-03190779>**

Submitted on 21 Nov 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**Fluoxetine for the symptomatic treatment of Multiple System Atrophy: the MSA-FLUO trial**

Olivier Rascol, MD, PhD<sup>1</sup>; Valérie Cochen De Cock, MD, PhD<sup>2</sup>; Anne Pavy-Le Traon, MD, PhD<sup>3</sup>; Alexandra Foubert-Samier, MD, PhD<sup>4</sup>; Claire Thalamas MD<sup>5</sup>; Agnès Sommet MD, PhD<sup>5</sup>; Vanessa Rousseau PhD<sup>5</sup>; Santiago Perez-Lloret MD, PhD<sup>6,21</sup>; Margherita Fabbri MD, PhD<sup>7</sup>; Jean Philippe Azulay MD, PhD<sup>8</sup>; Jean-Christophe Corvol MD, PhD<sup>9</sup>; Philippe Couratier, MD<sup>10</sup>; Philippe Damier MD, PhD<sup>11</sup>; Luc Defebvre MD, PhD<sup>12</sup>; Franck Durif MD, PhD<sup>13</sup>; Christian Geny MD<sup>14</sup>; Jean-Luc Houeto MD, PhD<sup>15</sup>; Philippe Remy MD, PhD<sup>16</sup>; Christine Tranchant, MD, PhD<sup>17</sup>; Marc Verin MD, PhD<sup>18</sup>; François Tison MD, PhD<sup>19</sup>; Wassilios G Meissner MD, PhD<sup>19,20</sup> for the MSA-FLUO Study Group

<sup>1</sup> French Reference Center for MSA, Centre d'Investigation Clinique de Toulouse CIC1436, Departments of Neurosciences and Clinical Pharmacology, NS-Park/FCRIN Network, NeuroToul COEN Center; University Hospital of Toulouse, INSERM, University of Toulouse 3; Toulouse; France

<sup>2</sup> Department of Neurology, Beau Soleil Clinic, Montpellier, France and EuroMov Digital Health in Motion, University of Montpellier IMT Mines Ales, Montpellier, France

<sup>3</sup> French Reference Center for MSA, Department of Neurosciences, Centre d'Investigation Clinique de Toulouse CIC1436; UMR 1048, Institute of Cardiovascular and Metabolic Diseases (I2MC); University Hospital of Toulouse, INSERM, University of Toulouse 3; Toulouse, France

<sup>4</sup> French Reference Centre for MSA, NS-Park/FCRIN Network; University Hospital Bordeaux, Bordeaux, FRANCE

<sup>5</sup> Centre d'Investigation Clinique de Toulouse CIC 1436; Department of Clinical Pharmacology; University Hospital of Toulouse, INSERM, University of Toulouse 3; Toulouse, France

<sup>6</sup> Biomedical Research Center, Interamerican Open University (CAECIHS-UAI), National Research Council (CONICET), Buenos Aires, Argentina

<sup>7</sup> Department of Neurosciences, Toulouse Parkinson Expert Center, Centre d'Investigation Clinique de Toulouse CIC1436, NS-Park/FCRIN Network; University Hospital of Toulouse, INSERM, University of Toulouse 3; Toulouse; France

<sup>8</sup> Aix-Marseille Université et Assistance Publique-Hôpitaux de Marseille ; Movement Disorders Unit; NS-Park/FCRIN Network. La Timone Hospital. Marseille. France

<sup>9</sup> Sorbonne Université, Assistance Publique Hôpitaux de Paris, Inserm, CNRS, Paris Brain Institute – ICM, Department of Neurology, Centre d'Investigation Clinique Neurosciences, NS-Park/FCRIN Network ; Pitié-Salpêtrière Hospital, Paris, France

<sup>10</sup> Centre de compétence AMS, NS-Park/FCRIN Network ; CHU Limoges ; Limoges France

<sup>11</sup> CHU Nantes, Inserm, Centre d'investigation clinique 0004, Hôpital Laennec, 44093 Nantes, France

<sup>12</sup> Service de Neurologie et Pathologie du Mouvement, NS-Park/FCRIN Network, CHU Lille, INSERM 1172, University of Lille ; Lille, France

<sup>13</sup> Neurology Department, University Hospital Center, Clermont-Ferrand, France; NS-Park/FCRIN Network ; Equipe d'Accueil 7280 Clermont Auvergne University, Clermont-Ferrand, France;

<sup>14</sup> EuroMov, University of Montpellier; Department of Neurology, CHRU Montpellier, Montpellier, France.

<sup>15</sup> Service de Neurologie, Centre Expert Parkinson, centre de compétence AMS, NS-Park/FCRIN Network ; CHU de Limoges, 87042 Limoges cedex, France

<sup>16</sup> Centre Expert Parkinson, NS-Park/FCRIN Network ; CHU Henri Mondor, AP-HP, Equipe NPI, IMRB, INSERM et Faculté de Santé UPE-C, Créteil

<sup>17</sup> Service de Neurologie, NS-Park/FCRIN Network, Hôpitaux Universitaires de Strasbourg; Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM-U964/CNRS-UMR7104/; Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France

<sup>18</sup> Centre Expert Parkinson – Bretagne, NS-Park/FCRIN Network ; University Hospital of Rennes; EA 4712 “Behavior and Basal Ganglia”, University of Rennes 1; Institut des Neurosciences Cliniques de Rennes, France ; Rennes, France

<sup>19</sup> Service de Neurologie des Maladies Neurodégénératives, French Reference Center for MSA, NS-Park/FCRIN Network, CHU Bordeaux, F-33000 Bordeaux, France and University of Bordeaux, CNRS, IMN, UMR 5293, F-33000 Bordeaux, France

<sup>20</sup> Dept. Medicine, University of Otago, Christchurch, and New Zealand Brain Research Institute, Christchurch, New Zealand

<sup>21</sup> Faculty of Medicine, Pontifical Catholic University of Argentina, Buenos Aires, Argentina

**Title:** 87 characters

**Word count:** Abstract n= ~~243~~250; Text n=2948

**References=** 45

**Figures=** 2

**Tables=** 3

**Running Title:** Fluoxetine for MSA patients

**Search Terms:** 1. Fluoxetine, 2. Multiple System Atrophy, 3. clinical trial, 4. placebo, 5. symptomatic treatment

**Financial Disclosure/Conflict of Interest:**

Authors have no disclosures related to the study.

**Study funding:**

Supported by the “Programme Hospitalier de Recherche Clinique” of the French Ministry of Health and Social Affairs (PHRC 2007 07-2001-01).

**Corresponding author**

Professor Olivier Rascol

Department of Clinical Pharmacology, Faculty of Medicine,

37 Allées Jules Guesde, 31000, Toulouse, France

Tel: +33 5 61 14 59 62 / Fax: +33 5 61 14 56 42

e-mail: [olivier.rascol@univ-tlse3.fr](mailto:olivier.rascol@univ-tlse3.fr)

Código de campo cambiado

**Abstract:**

**Background:** There are no effective treatments for multiple system atrophy (MSA).

Con formato: Fuente: Sin Negrita

**Objective:** To assess the efficacy and safety of the serotonin reuptake inhibitor fluoxetine (40 mg/day) for the symptomatic treatment of ~~multiple system atrophy~~ (MSA).

Con formato: Fuente: Sin Negrita

**Methods:** This was a double-blind, parallel-group, placebo-controlled, randomized (1:1) trial conducted in patients with “probable” MSA. The primary outcome was the change from baseline ( $\Delta$ ) to week-12 in the mean total score of the Unified MSA Rating Scale (UMSARS) Part I (historical review) + II (motor examination). Secondary outcomes included  $\Delta$ -to-week-6 in total UMSARS, and  $\Delta$ -to-week-12 in the Scales for Outcomes in Parkinson Disease-Autonomic Dysfunction, the Beck Depression Inventory, and the different domains of the MSA-Quality of Life questionnaire. Exploratory outcomes included  $\Delta$ -to-week-12 in UMSARS Part I and II separately, and  $\Delta$ -to-week-24 in total UMSARS.

**Results:** Eighty-one patients were randomized (40 to fluoxetine and 41 to placebo; mean age = 63 years; mean disease duration = 5 years). There was no significant difference in the primary outcome (treatment effect [95%CI], -2.13 units [-4.55;0.29],  $p=0.08$ ). There was a greater reduction on fluoxetine in  $\Delta$ -to-12-week in UMSARS Part II (exploratory outcome: -1.41 units [-2.84;0.03],  $p=0.05$ ) and in MSA-QoL emotional/social dimension (secondary outcome: -6.99 units [-13.40;-0.56],  $p<0.03$ ). Five deaths were reported (2 on fluoxetine and 3 on placebo). No unexpected adverse events were observed. Those

leading to treatment interruption or down titration were more frequent on fluoxetine.

**Conclusion:** The MSA-FLUO failed to demonstrate fluoxetine superiority over placebo on the total UMSARS score, but trends in motor and emotional secondary/exploratory outcomes deserve further investigation.

## Introduction

Multiple system atrophy (MSA) is an orphan, sporadic, devastating neurodegenerative disorder characterized by alpha-synuclein positive glial cytoplasmic inclusions and selective neurodegeneration in multiple brain areas.<sup>1,2</sup> The clinical phenotype of MSA encompasses a heterogeneous combination of symptoms related to autonomic dysfunction, poorly levodopa-responsive parkinsonism and cerebellar ataxia, leading to major disability and fatal outcome within few years.<sup>1,2</sup> The current treatments for MSA are extremely limited and disappointing,<sup>3</sup> with a major need for better interventions.<sup>4,5</sup> The serotonin systems degenerate in MSA, along with other neurotransmitters systems. A loss of serotonin neurons has been documented post-mortem in the brainstem of MSA patients.<sup>6,7</sup> Alterations of serotonin biomarkers have been reported in vivo in the CSF of patients with MSA<sup>8</sup> or using functional neuroimaging.<sup>9,10</sup> The contribution of serotonin mechanisms in the genesis of the motor and non-motor symptoms of MSA remains unclear. In animal models of parkinsonism, serotonin modulates the mesolimbic dopaminergic pathway and increases locomotor activity.<sup>11</sup> Serotonergic dysfunction has been involved in the pathophysiology of autonomic dysfunction, respiratory disturbances, apathy, pain and fatigue in MSA patients.<sup>12-14</sup> Paroxetine, a selective serotonin reuptake inhibitor (SSRI), has been reported to improve glottic stenosis in 3 patients with MSA.<sup>15</sup> Fluoxetine, another SSRI, may improve orthostatic hypotension in patients with Parkinson's disease (PD), although this has not been tested in MSA.<sup>16</sup> SSRIs are first line treatments for major depression in the general population<sup>17</sup> and depression is a common symptom in MSA.<sup>18</sup> SSRIs ameliorate

Código de campo cambiado

Código de campo cambiado

Código de campo cambiado

Código de campo cambiado

Código de campo cambiado

Código de campo cambiado

Código de campo cambiado

Con formato: Punto de tabulación: 5,25 cm, Izquierda

Código de campo cambiado

Código de campo cambiado

Código de campo cambiado

Código de campo cambiado

Código de campo cambiado

Código de campo cambiado

Código de campo cambiado

Código de campo cambiado

Código de campo cambiado

Código de campo cambiado

Código de campo cambiado



depressive symptoms in PD,<sup>19</sup> but this has never been assessed in MSA patients.

Código de campo cambiado

Serotonin can therefore be considered as a suitable therapeutic target for MSA, and medications like SSRIs, that have therapeutic value in relation to augmenting serotonergic neurotransmission, are available candidates. Such an approach has been rarely addressed in the past, with only one published randomized double-blind placebo-controlled study evaluating the effects of paroxetine.<sup>20</sup> The results of this pilot trial suggested that paroxetine may provide symptomatic benefit in MSA patients, although the small size of the sample (19 subjects) precluded definite conclusions. Therefore, the French Reference Center for MSA<sup>21</sup> and the French NS-Park/FCRIN network<sup>22</sup> set-up the MSA-FLUO trial to assess the symptomatic efficacy and safety of fluoxetine in patients with MSA.

Código de campo cambiado

Código de campo cambiado

Código de campo cambiado

## Methods

### Study design and patients

This was a 24-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, 2-arm clinical trial conducted by the French MSA national network of reference and competence centers across France (Aix-en-Provence, Bordeaux, Clermont-Ferrand, Dijon, Lille, Limoges, Marseille, Montpellier, Nantes, Paris-Henri Mondor, Paris-Pitié Salpêtrière, Poitiers, Rennes, Strasbourg, Toulouse), with the support of the French NS-PARK/FCRIN network. Patients were assessed at six consecutive visits: screening visit (within 4 weeks before baseline visit), week 0 (baseline), 6, 12, 24 and 28 (safety visit).

Patients were enrolled if they were aged between 30 and 80 years and if they were diagnosed with “probable” MSA according to international consensus diagnosis criteria.<sup>23</sup> Both parkinsonian (MSA-P) or cerebellar (MSA-C) phenotypes were eligible. Exclusion criteria were cognitive impairment precluding study evaluations, severe dysphagia making pill swallowing difficult, major depression disorder requiring specific treatment or having required any antidepressant agent during the 3 months preceding recruitment. Patients suffering from dementia (MMSE score < 24), wheel-chair bound or suffering from severe hyponatremia were also not included.

Active treatment consisted of fluoxetine 20 mg/day for the first 6 weeks and then 40 mg/day until the end of the 24th week. Treatment could be tapered off to the initial 20 mg/day dose if patients experienced unacceptable side effects. Treatment was tapered off during 1 week after week 24 and then interrupted, and a final safety visit was held at week 28.

Symptomatic treatments for autonomic or parkinsonian symptoms were allowed, providing that their dose had been stable for 2 months before entering into the study and was anticipated to remain unchanged during the study.

The study was registered in the ClinicalTrials.gov database (NCT number: NCT01146548). All patients signed informed consent before participating into the trial after ethical approval by the “Comité de Protection des Personnes Sud-Ouest et Outre-Mer II” and the French Drug Agency (AFSSAPS). The study was sponsored by the Toulouse University Hospital and funded by the “Programme Hospitalier de Recherche Clinique” of the French Ministry of Health and Social Affairs (PHRC 2007 07-2001-01).

Código de campo cambiado

### Randomization, treatments and masking

Balanced randomization in blocks of 4 was used, in a 1:1 ratio. The Pharmacy of the Toulouse University Hospital provided the computer randomization list. Subjects were randomized at baseline (week 0), after an eligibility assessment had been completed at a screening visit.

Fluoxetine hydrochloride was introduced at a dose of 20 mg/day (Prozac®, Eli Lilly) and then increased to 40 mg/day (2 x 20 mg pills) at the end of the 6<sup>th</sup> week. Matching placebo consisted in lactose pills with same color, odor and flavor as compared to fluoxetine. The investigators and personnel involved in patients' assessment, monitoring, analysis, and data management were masked to group assignment. Compliance was assessed by counting the difference in the number of pills delivered at a visit and brought back by the patients at the next visit. The proportion of patients with  $\geq 80\%$  compliance was assessed.

### Outcomes

The primary outcome was the mean change from baseline ( $\Delta$ ) to week-12 (month 3) in the total Unified MSA Rating Scale (UMSARS) Part I (historical review) + Part II (motor examination) score.<sup>24</sup> The same investigator of each MSA reference/competence center performed the UMSARS evaluation for a given patient. The choice of week-12 (month-3) to assess the primary outcome was made in order to reduce the risk of changes in concomitant symptomatic medications on longer follow-up (24 weeks).

Secondary outcomes included  $\Delta$ -to-week-6 in the mean scores of the total UMSARS,  $\Delta$ -to-week-12 in the Scales for Outcomes in Parkinson's Disease -

Código de campo cambiado

Autonomic Dysfunction (SCOPA-Aut) total score to assess autonomic disturbances,<sup>25</sup> in the Beck Depression inventory (BDI) to assess depressive symptoms,<sup>26</sup> and in the different dimensions of the MSA Health-Related Quality of Life (MSA-QoL) questionnaire (motor, non-motor, emotional/social scores & Health VAS).<sup>27</sup> Secondary outcomes, except UMSARS, were assessed at weeks 0 and 12 only.

Código de campo cambiado

Código de campo cambiado

Código de campo cambiado

Exploratory variables included  $\Delta$ -to-week-12 in the mean scores of UMSARS Part I and II assessed separately, and  $\Delta$ -to-week-24 in total UMSARS.

Survival, adverse events (AEs) and vital signs were recorded at each visit.

#### Statistical analysis

Quantitative variables were described by means and standard deviations, while number of cases and percentages were used for qualitative variables.

Differences across treatment groups were analysed by bivariate and multivariate techniques. Bivariate analysis included Chi-square or Fisher exact test for qualitative outcomes and T-test or Mann-Whitney test for the quantitative ones. Multivariate analyses were performed by linear regression, using treatment as an independent variable and including the following covariates recorded at baseline: age, UMSARS total (I+II) score, BDI score, disease duration and any other variable for which a significant between-group difference was found at baseline. Interaction between center and treatment was also studied and was not significant for any outcome.

Efficacy analysis was conducted in the intention to treat (ITT) population, defined as all randomized subjects. Imputation of missing data was performed by the Last Observation Carried Forward method (LOCF). Sensitivity analyses

included imputation by multiple regression and no imputation and analyses in the Full Analysis Set (FAS) defined as patients having received at least one dose of treatment and having at least one evaluation post-randomization. Safety data were evaluated for all randomized participants who took at least one dose of study drug.

Powering of the study estimated that a sample size of 33 subjects per group would provide a 90% power at a 5% difference level to detect a difference in the  $\Delta$  at week-12 in the UMSARS total score between fluoxetine and placebo, with an assumed difference of 4 UMSARS points and a standard deviation of 4 UMSARS points. A 25% drop-out rate was expected, and recruitment of 50 patients per group was therefore previewed.

## **Results**

Eighty-seven patients were screened, out of whom 81 were randomized, 40 to fluoxetine and 41 to placebo (ITT population) between June/2008 and October/2010. Two patients (both randomized to placebo) had no evaluation post-baseline (one patient died from suicide at week 4 and a second refused to come back after the baseline visit). The FAS population included therefore 79 patients, 40 on fluoxetine and 39 on placebo. Thirteen patients on fluoxetine and 10 on placebo dropped-out prematurely from the trial (Figure 1). The proportion of patients with compliance greater than 80% was similar among the placebo and fluoxetine groups (82% in both groups). A larger proportion of subjects in the placebo group (80%) reached and was maintained on the target dose (40 mg/d) as compared to the fluoxetine group (62%).

At baseline, there were no differences between the placebo and fluoxetine groups regarding demographics and outcomes data, except for a higher non-motor MSA-QoL sub-score and a shorter disease duration in the fluoxetine group (Table 1).

No significant between-group difference was observed in the primary outcome measure ( $\Delta$ -to-week-12 in total UMSARS score), although UMSARS total scores were numerically lower on fluoxetine than placebo at all visits, except baseline (Figure 2), and there was a trend in favor of a greater treatment-effect on fluoxetine (treatment effect [95%CI], -2.13 units [-4.55;0.29],  $p=0.08$ ).

Adjusted analyses are reported in Table 2. The treatment-effect was greater on fluoxetine at week-12 for the UMSARS Part II sub-score (exploratory outcome,  $p=0.05$ ) and for the emotional/social functioning sub-score of the MSA-QoL scale (secondary outcome,  $p=0.03$ ). No other differences were observed. Sensitivity analyses provided similar results (data not shown).

Five patients died during the trial: 3 in the fluoxetine group (one sudden death and two respiratory distress) and 2 in the placebo group (one suicide and one respiratory distress). None were considered to be related to treatment. Ninety-seven percent of patients on fluoxetine and 92% on placebo reported at least one Adverse Event (AE). Serious AEs were more frequently observed in patients randomized to fluoxetine than placebo (28% versus 17% respectively). Twenty-eight percent of patients on fluoxetine had an AE leading to treatment

premature interruption or down titration, as compared to 11% on placebo. The most relevant AEs are listed in Table 3.

## Discussion

The MSA-FLUO placebo-controlled randomized trial failed to demonstrate the superiority of fluoxetine on its primary outcome and must therefore be considered as a “negative” study. However, several trends in favor of fluoxetine were observed, including  $\Delta$ -to-week-12 changes in UMSARS total score (primary endpoint,  $p=0.08$ ), UMSARS motor examination sub-score (exploratory outcome,  $p=0.05$ ) and emotional/social functioning sub-score of the MSA-QoL scale (secondary outcome,  $p=0.03$ ). Trends supporting a potential short-term positive symptomatic effect of fluoxetine in MSA deserve discussion, as the treatment of this severe orphan disorder is limited to disappointing interventions supported by a low level of evidence.

Methodological issues must be discussed before considering any putative fluoxetine effects in MSA patients based on the present results. The dose of fluoxetine tested in the MSA-FLUO trial (40 mg/day) might not have been optimal to demonstrate full efficacy. Higher doses are known to be slightly more effective to treat major depressive disorders, but this benefit appears to plateau at 50 mg/day and is offset by decreased tolerability.<sup>28</sup> Twenty-eight percent of the MSA-FLUO patients did not tolerate the 40 mg/day dose, making the practical interest of higher doses unlikely in this population. Three months of follow-up are long enough to document the benefit of SSRIs in depressed

Código de campo cambiado

patients, and this may also apply to capture a symptomatic effect in MSA.<sup>29</sup> Conversely, it is possible that the MSA-FLUO study was underpowered to document a benefit, as the observed treatment effect (-2.13 UMSARS points) was smaller than the estimate for the sample size calculation (-4 UMSARS units), at threshold that reflects a clinically meaningful difference.<sup>30</sup> The trial also included patients with both MSA-P and MSA-C. This may have induced a greater variance than in trials focusing on MSA-P only,<sup>31</sup> further reducing the power of the study. The risk of having included some patients suffering from other disorders than MSA cannot be excluded in the absence of post-mortem neuro-pathological confirmation. However, all patients of the MSA-FLUO had a “probable” diagnosis of MSA<sup>23</sup>, established by experts from MSA reference/competence centers, in order to reduce the risk of false diagnosis. Finally, the MSA-FLUO population had a more advanced disorder at baseline (~5 years from diagnosis) than that of other trials which allowed including patients with “possible” MSA,<sup>31</sup> and one may speculate that the effect of fluoxetine could be greater at an earlier stage.

A first important practical conclusion of the MSA-FLUO study is that fluoxetine did not worsen patients’ disability, as monitored with the UMSARS in double-blind placebo-controlled conditions. Indeed, patients randomized to fluoxetine had consistently lower mean scores at each visit, except at baseline. SSRIs, including fluoxetine, are listed among the medications that can induce drug-induced parkinsonism.<sup>32</sup> Thus, the MSA-FLUO data provides evidence that using fluoxetine in MSA patients should not expose them to the risk of significant deterioration on the short-term.

Código de campo cambiado

Código de campo cambiado

Código de campo cambiado

Código de campo cambiado

Código de campo cambiado

Código de campo cambiado



At week-12, there was a trend in favor of fluoxetine in the UMSARS Part II (motor examination) sub-score ( $p=0.05$ ). This sub-score captures motor performance, as assessed by the investigator, as opposed to UMSARS Part I, which is a more global historical patient-reported review on oropharyngeal symptoms, difficulties in activities of daily living and dysautonomic symptoms.<sup>24</sup> UMSARS Part II is more sensitive than Part I to change over time in MSA prospective cohorts.<sup>33</sup> It is therefore conceivable that fluoxetine might have a greater impact on motor function than on other features of MSA, including autonomic ones. This assumption is consistent with the lack of effect observed on the SCOPA-Aut outcome in the same patients. The mechanisms underlying this potential motor effect remains speculative. Both MSA-P and MSA-C patients were included in the trial, and such an effect could then be equally driven by an effect of serotonin within the basal ganglia loops,<sup>34</sup> or within the cerebellar circuitry.<sup>35</sup> It is also possible that some positive effect on emotional features (see below) may have indirectly improved the motor behavior of the patients. Regardless of its underlying mechanisms, the amplitude of this putative motor effect is not expected to be dramatic (~1.5 units of the UMSARS motor score according to the present findings), although such an effect is still considered as clinically relevant.<sup>30</sup> Moreover, any symptomatic effect of fluoxetine in MSA is important to identify for research purposes, as this drug is listed among candidates for neuroprotective strategies in models of parkinsonism and MSA.<sup>36-38</sup> If fluoxetine is to be tested in the future using a disease-modifying trial design based on UMSARS outcomes, this effect might induce a significant confounding bias.<sup>39</sup>

Código de campo cambiado

Código de campo cambiado

Código de campo cambiado

Código de campo cambiado

Código de campo cambiado

Código de campo cambiado

Código de campo cambiado

A second signal detected in the MSA-FLUO trial was that patients randomized to fluoxetine had greater improvement in the emotional/social functioning sub-score of the MSA-QoL scale (p=0.03). Depression is a common and disabling symptom of MSA,<sup>40,41</sup> and correlates with poor QoL.<sup>42</sup> It is conceivable that the central serotonin deficiency observed in patients with MSA may participate into the genesis of depressive symptoms.<sup>6</sup> It is common practice to use SSRIs to treat depression in MSA,<sup>43</sup> in spite of the fact that their efficacy and safety have never been tested in this population. The emotional/social functioning dimension of the MSA-QoL scale includes ratings of fatigue, cognitive ability, depression and apathy.<sup>27</sup> It is unclear which of these domains could be influenced by fluoxetine. The lack of effect observed in the BDI score does not support a direct antidepressant effect, although this scale might not be the most appropriate one to detect an antidepressant effect in MSA, and the study was not powered for this outcome. It is interesting to note that worsening of depression or suicide ideation was reported as an adverse event in 11% of the patients randomized to placebo while none of the patients on fluoxetine reported such events (see Table 3). It is also possible that fluoxetine may act on other emotional features than depression, as correlations between fatigue scores and 5HT1A binding have been recently reported in vivo in MSA patients.<sup>14</sup> The level of evidence currently supporting the use of any intervention to manage emotional features in patients with MSA is based on empirical and anecdotal observations only. The MSA-FLUO findings support further assessment of the use of fluoxetine to manage such disabling symptoms in this severe orphan disorder.

Código de campo cambiado

Código de campo cambiado

Código de campo cambiado

Código de campo cambiado

Código de campo cambiado

Código de campo cambiado

Código de campo cambiado

No effects were observed on any other outcomes of the MSA-FLUO trial, including those addressing autonomic dysfunction, as measured by the SCOPA-Aut scale. Serotonergic systems are likely involved in the control of autonomic functions and their impairment in MSA could contribute to various aspects of autonomic dysfunction in this disorder.<sup>16</sup> It is possible that the SCOPA-Aut was not sensitive enough to detect changes induced by fluoxetine, while the study was not powered for that.

Código de campo cambiado

No unexpected adverse events were reported in the MSA-FLUO trial, as compared with the known safety and tolerability profile of the drug in patients suffering from psychiatric disorders. More patients on fluoxetine than placebo reported anorexia, weight loss or nausea as an adverse event during the trial, all well-known adverse reactions of the drug.<sup>44</sup> Five patients died during the study, three on fluoxetine and two on placebo. None of these deaths were considered to be related to treatment. Such a rate of death in this population is in line with the natural history of a severe disease like MSA, as four years since the first visit has been recently reported as the patients' median survival in the large French MSA cohort.<sup>45</sup>

Código de campo cambiado

Código de campo cambiado

In summary, the MSA-FLUO trial failed to demonstrate superiority of fluoxetine at the dose of 40 mg/day in the treatment of MSA. Several trends suggested however a possible partial improvement in motor and emotional/social functioning symptoms. Considering the paucity of efficacious treatments to manage such a severe disorder, and the existence of serotonergic

abnormalities in MSA, the findings of the MSA-FLUO trial warrant further investigation.

**Acknowledgements:** the authors wish to thank the patients who agreed to participate into the trial, and the staff of the French MSA competence centers, of the NS-Park/FCRIN network and of the Toulouse Clinical Investigation Center for their support in the management of the trial. Several authors of this publication are member of the European Reference Network for Rare Neurological Diseases - Project ID No 739510.

#### **Appendix 1. MSA-FLUO Study Group**

Aix-en-Provence : François Viallet, MD, Sophie Arguillère MD ; Clermont-Ferrand : Bérangère Debilly MD ; Dijon, Isabelle Bénatru MD ; Lille : Alain Destée, MD, David Devos, MD, PhD, Caroline Moreau, MD, PhD, Alexandra Kreisler, MD ; Limoges : Frédéric Torny MD ; Marseille : Dr Stéphanie Cantiniaux, MD, Tatiana Witjas ; Montpellier : Audrey Gabelle MD, William Camu ; Nantes : Pascal Derkinderen MD, PhD, Celine Deligny MD, Claire Meyniel, MD ; Paris-Henri Mondor : Gilles Fénélon MD ; Paris-Pitié Salpêtrière : Marie Vidailhet MD, PhD, Anne-Marie Bonnet MD, Frédéric Bloch MD, Emmanuel Roze MD, Lucette Lacomblez MD ; Poitiers: Pierre Jean Saulnier MD ; Rennes: Sophie Drapier, MD, Tiphaine Rouaud MD  
Strasbourg ; Matthieu Anheim MD, PhD ; Toulouse : Christine Brefel-Courbon, MD, PhD, Helene Catala MD, Fabienne Ory-Magne, MD, Monique Galitsky MD, Fabienne Calvas MD, Alice Seris, Gerard Tap, MD, PhD

## References

1. Stefanova N, Bucke P, Duerr S, Wenning GK. Multiple system atrophy: an update. *Lancet Neurol* 2009;8:1172-1178.
2. Meissner WG, Fernagut PO, Dehay B, et al. Multiple System Atrophy: Recent Developments and Future Perspectives. *Mov Disord* 2019;34:1629-1642.
3. Laurens B, Vergnet S, Lopez MC, et al. Multiple System Atrophy - State of the Art. *Curr Neurol Neurosci Rep* 2017;17:41.
4. Castro Caldas A, Levin J, Djaldetti R, et al. Critical appraisal of clinical trials in multiple system atrophy: Toward better quality. *Mov Disord* 2017;32:1356-1364.
5. Walsh RR, Krismer F, Galpern WR, et al. Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. *Neurology* 2018;90:74-82.
6. Benarroch EE, Schmeichel AM, Low PA, Parisi JE. Involvement of medullary serotonergic groups in multiple system atrophy. *Ann Neurol* 2004;55:418-422.
7. Tada M, Kakita A, Toyoshima Y, et al. Depletion of medullary serotonergic neurons in patients with multiple system atrophy who succumbed to sudden death. *Brain* 2009;132:1810-1819.
8. Laurens B, Constantinescu R, Freeman R, et al. Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative. *Neurobiol Dis* 2015;80:29-41.
9. Scherfler C, Seppi K, Donnemiller E, et al. Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. *Brain* 2005;128:1605-1612.
10. Lewis SJ, Pavese N, Rivero-Bosch M, et al. Brain monoamine systems in multiple system atrophy: a positron emission tomography study. *Neurobiol Dis* 2012;46:130-136.
11. Mylecharane EJ. Ventral tegmental area 5-HT receptors: mesolimbic dopamine release and behavioural studies. *Behav Brain Res* 1996;73:1-5.
12. Benarroch EE, Schmeichel AM, Low PA, Parisi JE. Depletion of putative chemosensitive respiratory neurons in the ventral medullary surface in multiple system atrophy. *Brain* 2007;130:469-475.
13. Cersosimo MG, Benarroch EE. Central control of autonomic function and involvement in neurodegenerative disorders. *Handb Clin Neurol* 2013;117:45-57.
14. Meyer M, Sibon I, Lamare F, et al. Brain 5-HT1A receptor binding in multiple system atrophy: A [18F]-MPPF PET study. Manuscript in preparation 2020.

15. Ozawa T, Sekiya K, Sekine Y, et al. Maintaining glottic opening in multiple system atrophy: efficacy of serotonergic therapy. *Mov Disord* 2012;27:919-921.
16. Montastruc JL, Pelat M, Verwaerde P, et al. Fluoxetine in orthostatic hypotension of Parkinson's disease: a clinical and experimental pilot study. *Fundam Clin Pharmacol* 1998;12:398-402.
17. Ryan M, Eatmon CV, Slevin JT. Drug treatment strategies for depression in Parkinson disease. *Expert Opin Pharmacother* 2019;20:1351-1363.
18. Benrud-Larson LM, Sandroni P, Schrag A, Low PA. Depressive symptoms and life satisfaction in patients with multiple system atrophy. *Mov Disord* 2005;20:951-957.
19. Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review. *Mov Disord* 2019;34:180-198.
20. Friess E, Kuempfel T, Modell S, et al. Paroxetine treatment improves motor symptoms in patients with multiple system atrophy. *Parkinsonism Relat Disord* 2006;12:432-437.
21. French Reference Center for MSA <https://www.chu-toulouse.fr/-centre-de-referance-de-l-atrophie-multisystematisee> (Accessed on 27/04/2020).
22. French NS-Park/FCRIN network. <https://parkinson.network/> (Accessed on 27/04/2020).
23. Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. *Neurology* 2008;71:670-676.
24. Wenning GK, Tison F, Seppi K, et al. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). *Mov Disord* 2004;19:1391-1402.
25. Visser M, Marinus J, Stiggelbout AM, Van Hilten JJ. Assessment of autonomic dysfunction in Parkinson's disease: the SCOPA-AUT. *Mov Disord* 2004;19:1306-1312.
26. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. *Arch Gen Psychiatry* 1961;4:561-571.
27. Schrag A, Selai C, Mathias C, et al. Measuring health-related quality of life in MSA: the MSA-QoL. *Mov Disord* 2007;22:2332-2338.
28. Jakubovski E, Varigonda AL, Freemantle N, Taylor MJ, Bloch MH. Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder. *Am J Psychiatry* 2016;173:174-183.
29. Stahl SM, Nierenberg AA, Gorman JM. Evidence of early onset of antidepressant effect in randomized controlled trials. *J Clin Psychiatry* 2001;62 Suppl 4:17-23.
30. Krismer F, Seppi K, Wenning GK, Abler V, Papapetropoulos S, Poewe W. Minimally clinically important decline in the parkinsonian variant of multiple system atrophy. *Mov Disord* 2016;31:1577-1581.
31. Poewe W, Seppi K, Fitzer-Attas CJ, et al. Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. *Lancet Neurol* 2015;14:145-152.
32. Bondon-Guitton E, Perez-Lloret S, Bagheri H, Brefel C, Rascol O, Montastruc JL. Drug-induced parkinsonism: a review of 17 years' experience in a regional pharmacovigilance center in France. *Mov Disord* 2011;26:2226-2231.

33. Wenning GK, Geser F, Krismer F, et al. The natural history of multiple system atrophy: a prospective European cohort study. *Lancet Neurol* 2013;12:264-274.
34. Inden M, Abe M, Minamino H, et al. Effect of selective serotonin reuptake inhibitors via 5-HT1A receptors on L-DOPA-induced rotational behavior in a hemiparkinsonian rat model. *J Pharmacol Sci* 2012;119:10-19.
35. Trouillas P, Xie J, Adeleine P. Buspirone, a serotonergic 5-HT1A agonist, is active in cerebellar ataxia. A new fact in favor of the serotonergic theory of ataxia. *Prog Brain Res* 1997;114:589-599.
36. Santos CM. New agents promote neuroprotection in Parkinson's disease models. *CNS Neurol Disord Drug Targets* 2012;11:410-418.
37. Peng T, Liu X, Wang J, et al. Fluoxetine-mediated inhibition of endoplasmic reticulum stress is involved in the neuroprotective effects of Parkinson's disease. *Aging (Albany NY)* 2018;10:4188-4196.
38. Shadfar S, Kim YG, Katila N, et al. Neuroprotective Effects of Antidepressants via Upregulation of Neurotrophic Factors in the MPTP Model of Parkinson's Disease. *Mol Neurobiol* 2018;55:554-566.
39. Athauda D, Foltynie T. Challenges in detecting disease modification in Parkinson's disease clinical trials. *Parkinsonism Relat Disord* 2016;32:1-11.
40. Siri C, Duerr S, Canesi M, et al. A cross-sectional multicenter study of cognitive and behavioural features in multiple system atrophy patients of the parkinsonian and cerebellar type. *J Neural Transm* 2013;120:613-618.
41. Schrag A, Sheikh S, Quinn NP, et al. A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. *Mov Disord* 2010;25:1077-1081.
42. Schrag A, Geser F, Stampfer-Kountchev M, et al. Health-related quality of life in multiple system atrophy. *Mov Disord* 2006;21:809-815.
43. Rey MV, Perez-Lloret S, Pavy-Le Traon A, Meissner WG, Tison F, Rascol O. A cross-sectional study on drug use in multiple system atrophy. *CNS Drugs* 2014;28:483-490.
44. Domecq JP, Prutsky G, Leppin A, et al. Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis. *J Clin Endocrinol Metab* 2015;100:363-370.
45. Foubert-Samier A, Pavy-Le Traon A, Guillet F, et al. Disease progression and prognostic factors in multiple system atrophy: A prospective cohort study. *Neurobiol Dis* 2020;139:104813.

Figure 1. Study flow chart (ITT: intention-to-treat; FAS: full analysis set)






Figure 2. Changes from baseline to Week 24 in UMSARS I+II score in the ITT population (placebo =41; Fluoxetine = 40). No significant between-group differences were observed at any visit (primary study outcome measure: Week 12).




Table 1. Demographics and outcomes at baseline [ITT population; Means  $\pm$  Standard deviations or n (%)] (LEDD: levodopa equivalent daily dose)

	Placebo (n=41)	Fluoxetine (n=40)	p-value
Age	63.5 $\pm$ 8.1	63.1 $\pm$ 7.8	0.82
Females	17 (41.5%)	14 (35.0%)	0.55
Weight	75.8 $\pm$ 15.5	73.1 $\pm$ 16.5	0.73
MSA "probable"	41 (100%)	40 (100%)	-
MSA type "P"	20 (48.8%)	24 (60.0%)	0.31
Disease duration	6.4 $\pm$ 4.0	4.6 $\pm$ 2.1	0.04
LEDD	458.6 $\pm$ 496.5	487.5 $\pm$ 517.4	0.75
UMSARS I+II	40.2 $\pm$ 13.3	40.3 $\pm$ 12.1	0.97
UMSARS I	18.7 $\pm$ 6.9	19.2 $\pm$ 6.5	0.95
UMSARS II	21.5 $\pm$ 7.3	21.1 $\pm$ 6.4	0.85
SCOPA-Aut	20.4 $\pm$ 8.3	23.4 $\pm$ 8.8	0.19
BDI	11.1 $\pm$ 6.6	12.4 $\pm$ 7.3	0.50
MSA-QoL scale			
Motor	44.4 $\pm$ 19.5	46.8 $\pm$ 20.3	0.72
Non-motor	34.3 $\pm$ 17.3	42.6 $\pm$ 18.3	0.04
Emotional/social functioning	31.8 $\pm$ 20.5	38.1 $\pm$ 22.1	0.27
Health VAS	49.0 $\pm$ 17.8	46.2 $\pm$ 22.0	0.66

Table 2. Study outcomes at Week 12 (ITT population, means  $\pm$  Standard deviations)

	Score at Week 12		Treatment effect (95% CI) Adjusted	p-value
	Placebo	Fluoxetine		
	N=41	N=40		
UMSARS I+II	43.3 $\pm$ 14.0	41.6 $\pm$ 13.7	-2.13 (-4.55;0.29)	0.08
UMSARS I	20.3 $\pm$ 6.9	20.2 $\pm$ 6.6	-0.72 (-2.23;0.79)	0.34
UMSARS II	23.0 $\pm$ 7.8	21.4 $\pm$ 7.8	-1.41 (-2.84;0.03)	0.05
SCOPA-Aut total	20.3 $\pm$ 8.9	23.2 $\pm$ 8.4	0.05 (-2.93;3.03)	0.97
BDI	12.7 $\pm$ 7.8	13.4 $\pm$ 7.9	-0.47 (-3.31;2.38)	0.74
MSA-QoL scale				
Motor	47.3 $\pm$ 22.4	45.4 $\pm$ 18.8	-4.26 (-10.50;1.99)	0.18
Non-motor	33.4 $\pm$ 18.2	39.1 $\pm$ 19.1	-3.16 (-9.35;3.02)	0.31
Emotional/social	33.2 $\pm$ 21.3	31.5 $\pm$ 17.4	-6.99 (-13.40;-0.56)	0.03
Health VAS	50.3 $\pm$ 20.9	47.6 $\pm$ 20.2	-0.67 (-10.7;9.37)	0.89

Table 3. Most relevant Adverse Events (Number of cases and %).

	Placebo (n=39)	Fluoxetine (n=40)
Worsening of depression	3 (8%)	0
Suicidal ideation	1 (3%)	0
Anxiety	2 (5%)	1 (3%)
Agitation	1 (3%)	5 (13%)
Insomnia	1 (3%)	3 (8%)
Anorexia/Weight loss	7 (18%)	14 (35%)
Tremor	2 (5%)	5 (13%)
Nausea	3 (8%)	6 (15%)